Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jd9919 jd9919 Mar 14, 2013 3:05 PM Flag

    Analyst remarks

    Greg Wade, Wedbush (3/11/13) "OncoGeneX Pharmaceuticals Inc. reported Q4/12 earnings per share of ($0.28) based on timing of collaboration revenue from Teva Pharmaceutical Industries Ltd., ending the year with $75.7M in cash. . .the key catalyst for OncoGeneX shares remains data from the phase 3 Synergy trial of OGX-011 (custirsen) in the H1/14 time frame. . .we reiterate our Outperform rating."

    Douglas Loe, Byron Capital Markets (3/8/13) "There is no change in our valuation or investment theses or positive view on the medical potential of OncoGeneX Pharmaceuticals Inc.'s OGX-011 in castrate resistant prostate cancer, with OGX-427 providing future upside to our forecasts; we maintain our Buy rating and $30.50 target. . .the company continues to drive clinical programs for both OGX-011 and OGX-427 in what is among the most robust clinical pipelines in our coverage universe."

    Philippa Flint, Bloom Burton & Co. (3/8/13) "We continue to rate OncoGenex Pharmaceuticals Inc. shares positively as we believe the company's shares are attractively valued for risk-tolerant investors. Pivotal phase 3 data is expected around year-end for custirsen in first-line prostate cancer. . .we are encouraged by the survival data seen in phase 2. . .and recommend investors buy shares at current levels, as we expect them to gain in value in H2/13 as we approach phase 3 data readout."

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OGXI
2.08-0.07(-3.26%)Apr 1 4:00 PMEDT